Answers are grounded in this paper and cite their sources.
Introduction and Objective: The primary focus of this study is to compare the magnitude of HbA1c and GMI reduction in diabetic patients who are continuous glucose monitor (CGM)-naïve versus those transitioning from transcutaneous sensors. The study aims to determine the glycemic benefit of initiating an implantable CGM and whether transitioning to an implantable sensor provides superior clinical outcomes compared to traditional transcutaneous systems. Methods: This single-center, 14-month study (Nov 2024-Dec 2025) analyzed n = 44 diabetic patients (mean age 67.16). Inclusion criteria required wear time > 75%, device duration > 3 months, and complete glycemic data. The cohort (mean wear time 93.8% ± 4.91%) included 38 patients on multiple daily injections and 27 on GLP-1 therapies. Paired t-tests assessed significance at 3 and 6 months. Results: Baseline HbA1c for the entire cohort was 7.85% ± 1.94% (Naïve: 8.88% ± 2.83%; Prior transcutaneous: 7.51% ± 1.80%; Prior Eversense: 7.99% ± 0.91%; Prior dual-experienced with both transcutaneous and Eversense: 7.44% ± 1.59%). Total mean cohort Time in Range (TIR) was 78.11% ± 14.88%. Time spent 54-70 mg/dL was 1.23% ± 1.47%. Mean time below 54 mg/dL was 0.18% ± 0.28%. Post-initiation mean GMI at 2 weeks was 6.79% ± 0.49% (Naïve: 6.72% ± 0.25%; Prior transcutaneous: 6.78% ± 0.59%; Prior Eversense: 7.11% ± 0.44%; Dual: 6.62% ± 0.41%). At 3 months (n = 39), mean HbA1c reduction was 0.72% (p = 0.0068); naïve patients achieved 1.57% reduction and experienced patients achieved 0.53% (p = 0.0174). At 6 months (n = 27), mean reduction was 0.33% for the whole cohort. Conclusion: Significant reductions in HbA1c and GMI indicate rapid stabilization upon initiating an implantable sensor. Naïve patients experienced a larger reduction. These outcomes exceed previously published results. Future analysis will calculate if implantable CGM usage results in fewer hospitalizations or ED visits compared to transcutaneous sensors or no CGM. Disclosure R. Tandon: None. J.B. Torres Serrano: None. B. Muldrow: None. S. Noorali: None. B.S. Baliga: Speaker's Bureau; Current; Abbott Diabetes. Speaker's Bureau; Ended; Novo Nordisk. Speaker's Bureau; Current; Boehringer Ingelheim International GmbH. Speaker's Bureau; Ended; AstraZeneca. Speaker's Bureau; Current; Beta Bionics, Inc. Stock/Shareholder; Current; Beta Bionics, Inc. Speaker's Bureau; Current; Xeris Pharmaceuticals, Inc., Eli Lilly and Company.
No takes yet. Share an insight, caveat, or question.
TANDON et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: